Clomid is an oral fertility medicine for women whose ovaries do not release eggs regularly. Its active ingredient, clomifene citrate, reduces estrogen feedback to encourage the pituitary gland to release hormones that support follicle development and ovulation.
Clomid is an oral tablet containing clomifene citrate, a selective estrogen receptor modulator used to induce ovulation. It is prescribed mainly for women with anovulatory infertility, including infertility associated with polycystic ovary syndrome. By reducing estrogen feedback to the hypothalamus, Clomid increases pituitary release of FSH and LH, helping a developing follicle mature and release an egg.
The dose is stated on the pack — follow the leaflet. The active substance is a non-steroidal SERM with activity at estrogen receptors involved in hypothalamic feedback.
The therapeutic aim is not to supply estrogen. It is to modify estrogen feedback temporarily so the reproductive hormone system increases FSH and LH secretion.
The US Food and Drug Administration prescribing information describes its use for ovulatory dysfunction in women wishing to become pregnant [1].
The dose is stated on the pack — follow the leaflet.
A typical cycle may follow this pattern:
Some treatment protocols begin around cycle day 2, 3, 4, or 5. The appropriate start depends on the menstrual pattern and the clinician’s fertility strategy. A higher daily dose may be considered after a non-ovulatory course, but dose escalation should not be self-directed.
Treatment duration is limited because repeated exposure can increase cumulative concerns, including visual symptoms and ovarian complications. The FDA prescribing information describes stepwise dose adjustment and limits prolonged treatment when ovulation does not occur .
Clomid may be taken with or without food. Taking it at the same time each day can make the treatment schedule easier to follow. Nausea or flushing may feel more noticeable at certain times, so some patients prefer an evening dose when their clinician permits that timing.
A SERM binds to estrogen receptors and produces different effects in different tissues. In the hypothalamus, clomifene reduces the perceived estrogen signal. The brain responds by increasing gonadotropin-releasing hormone activity, which encourages the pituitary gland to release follicle-stimulating hormone and luteinizing hormone.
Clomid influences the hypothalamic–pituitary–ovarian axis. This system links brain hormone signals with ovarian follicle development and ovulation. Its activity changes across the menstrual cycle. The hypothalamus, pituitary gland, and ovaries communicate through coordinated hormone signals.
FSH supports growth of ovarian follicles. LH contributes to follicular maturation and triggers ovulation after the dominant follicle has developed. When clomifene blocks estrogen feedback at the hypothalamus, the pituitary receives a weaker signal that estrogen activity is sufficient. FSH and LH secretion may then rise, supporting follicle recruitment and ovulation.
Clomifene citrate is used for anovulatory infertility, meaning the ovaries do not release an egg regularly. Polycystic ovary syndrome is a common cause of irregular or absent ovulation, although the medicine is not suitable for every person with PCOS.
Patients may be considered for Clomid when:
Clinical fertility assessment may include menstrual history, ovulation testing, pelvic ultrasound, thyroid evaluation, prolactin measurement, ovarian reserve testing, and semen analysis when relevant. Clomid cannot correct blocked fallopian tubes, severe male-factor infertility, or infertility caused by conditions that require another treatment.
The World Health Organization identifies ovulatory disorders as an important category of infertility requiring targeted diagnosis and treatment. Its infertility guidance published in 2023 supports an individualised approach rather than treating every irregular menstrual cycle with the same medicine [2].
A fertility clinician often explains the goal in practical terms: produce one mature follicle and predictable ovulation, not simply raise hormone levels. Excessive ovarian response can increase the chance of multiple pregnancy and requires clinical supervision.
Clomid and generic clomiphene citrate contain the same active pharmaceutical substance when the strength and formulation are equivalent. The clinical difference usually relates to treatment planning, excipients, tablet supply, and the patient’s monitored response rather than a different ovulation mechanism.
| Treatment approach | Main mechanism | Clinical distinction |
|---|---|---|
| Clomid or equivalent clomifene citrate | SERM that reduces hypothalamic estrogen feedback | Oral ovulation induction with a defined five-day course |
| Letrozole | Aromatase inhibition lowers estrogen production temporarily | An alternative ovulation-induction approach, often considered in PCOS |
| Gonadotropin injections | Direct stimulation with FSH or related hormones | Requires closer ultrasound monitoring and carries a higher risk of excessive ovarian response |
Enclomifene and zuclomifene are stereoisomers associated with clomifene citrate. Clomifene citrate contains a mixture of isomeric forms with different persistence and estrogen-receptor activity. Enclomifene has been studied as a separate hormonal compound, but it should not be treated as interchangeable with the tablets supplied for Clomid treatment.
Letrozole may be selected for some patients with PCOS, while injectable gonadotropins may be considered when oral induction is unsuccessful or when assisted reproductive treatment is planned. The choice depends on age, ovarian reserve, ovulation history, body weight, semen analysis, tubal findings, and previous treatment response.
Clomid is not suitable in several situations. A fertility clinician should establish the cause of infertility and exclude pregnancy before treatment begins.
Clomid is not for you if you have:
Treatment should also be reconsidered when pelvic pain, enlarged ovaries, severe endometriosis, or a high risk of ovarian hyperstimulation is present. Clomid does not treat the underlying cause of every infertility pattern.
The most common effects are linked to hormonal stimulation and estrogen-receptor modulation. Patients may experience hot flushes, headache, breast discomfort, nausea, mood changes, abdominal discomfort, or bloating.
Visual symptoms deserve special attention. Blurred vision, flashing lights, spots, or difficulty focusing can occur and may persist after treatment. Clomid should be stopped and urgent medical advice obtained if visual symptoms develop, because continuing treatment after these symptoms may increase the risk of prolonged visual disturbance.
Other clinically significant risks include:
The response can be emotionally demanding. A patient may ovulate successfully yet not conceive in that cycle. Clomid improves the chance of ovulation; it does not guarantee fertilisation or pregnancy.
Some patients report that hot flushes are easier to manage with light clothing, cool fluids, and avoidance of overheated rooms. A new headache may be mild, but a severe headache accompanied by visual changes requires prompt medical review rather than another dose.
Several errors can reduce the value of an otherwise appropriate treatment plan:
A common misconception is that a stronger dose always produces a better chance of pregnancy. More ovarian stimulation can raise the risk of multiple follicles, ovarian enlargement, and multiple pregnancy without producing a proportional benefit.
In clinical practice, the most useful measure is ovulation confirmed through an appropriate monitoring plan, not a change in menstrual symptoms alone. Regular bleeding does not always prove that an egg was released.
Doctors also assess whether the uterine lining and cervical mucus remain favourable. Clomifene’s anti-estrogen effects may help ovulation while producing less favourable conditions for conception in some treatment cycles.
The European Medicines Agency guidance on medicines used for female infertility emphasises careful patient selection, cycle monitoring, and attention to ovarian response. A clinician will usually review the number and size of follicles before advising intercourse timing, intrauterine insemination, or a further treatment cycle [3].
One practical issue is timing. Ovulation may occur several days after the final tablet, so relying on a single calendar date can lead to missed fertile days. The fertility team may recommend urine LH testing, ultrasound, or a timed trigger depending on the protocol.
Clomid may be used for anovulatory infertility associated with PCOS when the ovaries can respond to stimulation. The WHO infertility guideline published in 2023 describes ovulatory dysfunction as a condition requiring cause-specific management. The medicine is selected after pregnancy, thyroid problems, prolactin abnormalities, and other fertility factors have been assessed.
Ovulation often occurs several days after the five-day tablet course, although the exact timing varies between patients. The FDA prescribing information issued for Clomid in 2012 describes cycle-based dosing rather than a guaranteed ovulation date. Ultrasound, urine LH testing, or progesterone testing can provide a more reliable assessment than symptoms alone.
Clomid should not be taken during pregnancy. The European Medicines Agency fertility-medicine guidance published in 2018 requires pregnancy status to be considered before ovulation-induction treatment begins. A positive pregnancy test after treatment should be reported to the fertility clinician before any further tablet is taken.
Blurred vision, flashes, spots, or difficulty focusing require prompt medical assessment, and further Clomid doses should not be taken until the prescriber gives specific instructions. The FDA Clomid prescribing information from 2012 describes visual disturbances as a reason for stopping treatment and evaluating the patient. Persistent symptoms need urgent ophthalmic or medical review.
Clomid can induce ovulation in suitable patients, but ovulation does not guarantee fertilisation or implantation. The American Society for Reproductive Medicine guideline published in 2020 explains that fertility treatment success also depends on age, sperm factors, tubal function, ovarian reserve, and the cause of infertility. A treatment cycle should therefore be judged by monitored ovulation and the wider fertility plan.
Clomid increases the likelihood of multiple pregnancy because more than one follicle may mature. A Cochrane review published in 2019 discussed the risk of multiple pregnancy and the uncertainty surrounding outcomes across different infertility populations. Follicle monitoring helps the clinical team assess whether the response is too strong for safe continuation.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I had irregular cycles related to PCOS. Ovulation was confirmed on ultrasound after the first course, but pregnancy did not happen that month. The hot flushes were manageable, while the waiting period was harder than I expected.
The tablets were easy to take, and my cycle became more predictable. I noticed headaches on two evenings and reported them before the next cycle. The clinic changed the monitoring plan rather than simply increasing the dose.
I mistakenly started two days early because I counted the cycle incorrectly. The clinic told me not to add tablets and arranged a new plan for the following cycle. The experience taught me that timing matters more than guessing.
I developed flashing lights while reading during the treatment week. I stopped the tablets and contacted the clinic immediately. The symptom settled, but I did not restart treatment until the clinician had reviewed me.
